Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.
The benefits of receiving SARS-CoV-2 neutralizing mAb infusions do NOT include:
2.
Which of the following is true about SC administration of casirivimab + imdevimab?
3.
Which of the following patients would NOT be a candidate for mAb infusion?
4.
Which mAbs are NOT effective against the delta variant?
5.
Which EUA approved mAb is stable for up to 36 hr once refrigerated after reconstitution?
6.
Which route is NOT authorized for pharmacists to administer treatment under DHHS PREP Act?